Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlook
- 1 April 2016
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 53, S39-S42
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals of the Rheumatic Diseases, 2013
- A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopeniaHaematologica, 2013
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- Prise en charge du purpura thrombopénique immunologique en France avant la mise à disposition des agonistes du récepteur à la thrombopoïétineLa Revue de Médecine Interne, 2012
- Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopeniaBlood, 2011
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agentsBlood, 2010
- Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population‐based cohort studyBritish Journal of Haematology, 2010
- Case 11-2010New England Journal of Medicine, 2010
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseHaematologica, 2010
- Repeated courses of rituximab in chronic ITP: Three different regimensAmerican Journal of Hematology, 2009